Phase A — Understand the business
Lens 1 · Company Overview
Rocket Lab is the only Western company that does both ends of the space value chain at commercial scale: it builds and flies its own rockets and builds the satellites (and, increasingly, the satellite components and payloads) that ride on them. Two reporting engines:
- Launch Services — the Electron small-lift rocket (the workhorse: 50+ successful orbital launches, the second-most-launched US rocket after Falcon 9), plus HASTE, a suborbital hypersonic-test variant that has quietly become a real defense revenue line. The forthcoming Neutron medium-lift reusable rocket (~13,000 kg to LEO) is the franchise-defining bet — it moves Rocket Lab from the niche small-sat market into the megaconstellation/national-security launch market dominated by SpaceX.
- Space Systems — satellite buses (Photon), reaction wheels & star trackers (Sinclair), separation systems (Planetary Systems), flight software (ASI), space solar cells (SolAero — "world's largest production line of space solar cells"), EO/IR national-security payloads (Geost, acquired Aug 2025), laser optical comms terminals (Mynaric, closed Apr 2026), and a new electric-propulsion line (Gauss) and a mass-producible flat satellite (Flatellite). Space Systems is now ~60–68% of revenue.
Customers: a commercial + government mix — NASA, the U.S. Space Force / Space Development Agency (SDA), commercial constellation operators, and defense primes. Contract structure: lumpy, milestone- and delivery-based (launch slots, satellite-build programs), increasingly anchored by multi-year government primes — the SDA Tracking Layer work alone is ~$1.3B of contracted backlog.
Headline scale (calendar Q1 2026, ended Mar 31 2026): revenue $200.3M, +63.5% YoY, a company record; total backlog >$2.2B, +~108% YoY.
Lens 2 · Supply Chain
Map: inputs → Rocket Lab → end customer. Rocket Lab's defining strategic move is that it has spent the last six years acquiring its own upstream, so much of the chain is now in-house.
Upstream inputs (what it buys / makes):
- Carbon composite (Neutron structures, Electron) — internally fabricated; a differentiator and a chokepoint (specialized autoclaves, the "Hungry Hippo" reusable fairing).
- Propulsion — Rutherford engines (Electron, 3D-printed, electric-pump-fed) and Archimedes (Neutron, methalox, 1.5M lbf) — both designed and built in-house. Archimedes qualification is the gating critical-path item for Neutron.
- Satellite subsystems — now owned: reaction wheels/star trackers (Sinclair Interplanetary, 2020), separation systems (Planetary Systems Corp, 2021), flight software (ASI Aerospace, 2021), space solar cells (SolAero, $80M, Jan 2022), EO/IR payloads (Geost, $275M, Aug 2025), laser comms terminals (Mynaric, $155.3M, Apr 2026).
- Still bought out: raw avionics chips, propellant (LOX/methane/kerosene), certain ground-segment hardware, launch-range services (it operates LC-1 in New Zealand and LC-2/LC-3 at Wallops, Virginia).
Chokepoints / single-source dependencies:
- Archimedes engine = the single most important chokepoint for the entire equity story. No Archimedes qualification → no Neutron → no medium-lift TAM.
- Mahia (NZ) launch range for Electron — geographic + regulatory single point; weather/permit sensitivity.
- Vertical integration cuts both ways: owning SolAero/Geost/Mynaric removes external-supplier risk but converts it into execution + integration + capex risk on Rocket Lab's own balance sheet.
End customers (named): NASA, U.S. Space Force / SDA, the MDA/"Golden Dome" missile-defense architecture, commercial constellation operators (incl. an undisclosed large constellation customer behind the record multi-launch Neutron deal), and satellite-component buyers who purchase Rocket Lab's merchant products (solar cells, reaction wheels, now Gauss propulsion and Mynaric terminals as a merchant supplier).
This lens passes the "names or it didn't happen" test: the chain is largely a list of companies Rocket Lab now owns.
Lens 3 · Competitive Advantages (moats)
The moat thesis is "the only credible Western full-stack alternative to SpaceX." Specifically:
- Proven launch cadence + reliability (real, durable). Electron is the only small-lift Western rocket with a deep, repeatable track record (50+ orbital launches; FY2025 flew 21 missions across Electron+HASTE at a 100% success rate). Reliability is the single hardest thing to fake in launch and the deepest switching cost — payload customers underwrite years of mission planning to a vehicle.
- Vertical integration (real, but double-edged). Owning launch + bus + components + payloads + comms means Rocket Lab can sell a constellation-as-a-product (design → build → launch → operate) that almost no one else can. Flatellite + Neutron + Geost/Mynaric payloads is the embodiment. The bargaining-power asymmetry: constellation customers increasingly need an alternative to SpaceX more than Rocket Lab needs any single one of them — that's pricing power, on the launch side.
- National-security entrenchment (strengthening fast). The $816M SDA Tracking Layer Tranche 3 prime (Dec 2025) + Geost EO/IR payloads put Rocket Lab inside the US missile-warning/tracking architecture — a moat made of clearances, qualified processes, and ITAR that takes years and a security posture to replicate.
- Founder-engineer IP culture (Peter Beck). In-house Rutherford/Archimedes + composites = a process/IP moat, not just a brand.
Where the moat is weaker than bulls claim: on the launch economics axis, Rocket Lab is a price-taker to SpaceX, not a price-setter (see Lens 13). Its moat is "differentiated alternative + national-security trust," not "lowest cost per kilogram." That distinction is the whole bear case.
Lens 4 · Segments
No segments.csv in the research layer — all figures `` from the company's own 8-K releases. Rocket Lab reports revenue split as Launch Services vs. Space Systems, and separately as Product vs. Service.
| Period | Total rev | Launch Services | Space Systems | Notes |
|---|
| Q1 2026 (Mar-qtr) | $200.3M (+63.5% YoY) | $63.7M (+78.9% YoY; −16.1% QoQ on fewer launches) | $136.7M (+57% YoY; ~68% of mix) | record quarter |
| FY2025 | $601.8M (+38% YoY) | n/a split — not cleanly broken out | — | Product rev $371.6M / Service rev $230.2M |
| Q4 2025 | $179.7M | — | — | Product $94.0M / Service $85.6M |
| Q3 2025 | $155.0M (+48% YoY) | — | — | record GM at the time |
Trend & cause:
- Space Systems is the growth + mix story — it's ~60–68% of revenue and rising, driven by SDA satellite builds + solar/components + the Geost/Mynaric payload stack. This is accelerating and is what's converting Rocket Lab from "a launch company" into "a space prime."
- Launch Services is lumpier — grew ~79% YoY in Q1'26 but fell sequentially on launch timing; HASTE hypersonic-test cadence is the surprise contributor. Launch is the lower-revenue, higher-strategic-optionality segment today; Neutron is what re-rates it.
- Geography: not cleanly disclosed by segment; manufacturing is US (Long Beach CA, Albuquerque, Virginia) + New Zealand (Mahia launch + production). US-government revenue mix is rising with SDA/defense.
Phase B — Measure performance
Lens 5 · Earnings Result (latest print: Q1 2026, reported May 7 2026)
The cleanest "beat-and-raise" the company has printed.
- Revenue $200.3M, +63.5% YoY, above the $185–200M guide and above the ~$190.9M Street estimate. First-ever $200M quarter.
- Margins beat: GAAP gross margin 38.2% (guide 34–36%); non-GAAP 43.0% (guide 39–41%). Upside from better launch-cost absorption + strong solar-products performance.
- Adjusted EBITDA loss $(11.8)M — materially better than the guided $(21)–(27)M loss; the loss is shrinking fast.
- GAAP net loss per share $(0.07) — narrowing.
- Balance sheet: cash & equivalents ~$1.48B (up sharply from $828.7M at YE2025 — a capital raise during the quarter), giving multi-year Neutron runway. Non-GAAP FCF use $(77.4)M, improved from $(114.2)M in Q4'25.
- Backlog >$2.2B, +~108% YoY, on a record bookings quarter (31 Electron/HASTE missions + 5 Neutron contracts incl. the largest-ever multi-launch Neutron deal).
- Guidance (Q2 2026): revenue $225–240M (+~16% sequential midpoint); GAAP GM 33–35%, non-GAAP 38–40% (a step-down on Space Systems mix shift); adj. EBITDA loss $(20)–(26)M.
Unusual vs. its own history: the margin beat + EBITDA-loss compression + raised guide is the inflection bulls have waited for. The one yellow flag is the Q2 gross-margin guide stepping back down (mix shift to lower-margin Space Systems builds) — margins are not yet on a clean monotonic path. Market reaction: the stock has been a momentum rocket — +366% YoY, 52-wk range $25.71–$151.00, ATH close $150.23 (May 27 2026) — so beats are increasingly expected, not rewarded.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts/ in the research layer; sentiment read from web transcripts of the last ~4 calls.
- Tone has shifted from "building" to "executing/scaling." Q1'26 (Beck): "the demand signal is clear," the product cadence is "relentless," an "incredibly strong position to continue expanding." He flags record backlog, record cash, record launch contracts.
- The recurring phrase across 2025→2026 calls is "end-to-end space company" — every acquisition (Geost, Mynaric) and product (Flatellite, Gauss) is narrated as a step toward owning the full constellation stack. This is consistent and credible, not a pivot.
- What they keep hedging on: Neutron timing. Beck is candid that "many customers are waiting for the inaugural flight" — i.e., the order book has a Neutron-shaped ceiling until it flies. The honest acknowledgment (vs. promotional hand-waving) is a positive governance signal.
- What they stopped saying: hard first-launch dates for Neutron. After the Nov 2025 slip (2025 → 2026), management shifted to "arrives at LC-3 in Q1 2026, first launch thereafter pending qualification" — deliberately softer.
Net sentiment trend: rising confidence on the commercial/Space-Systems engine; disciplined caution on Neutron. The mix is appropriate and, frankly, more trustworthy than a pure-hype space-SPAC narrative.
Lens 7 · Comps
Provenance-critical lens. Multiples are `` with source/date or n/a. Peers pulled from _index.json (space topic) + obvious adds (ASTS).
| Company | Ticker | Mkt cap | EV/Sales | EV/EBIT | P/E | Div yield | 5-yr avg ROE | Note |
|---|
| Rocket Lab | RKLB | ~$60.7B | ~63.9x TTM | n/a — negative EBIT | n/a — loss-making | 0% | negative | full-stack launch+systems |
| Planet Labs | PL | n/a | n/a (RPO +361% to $672M ) | n/a | n/a | 0% | negative | EO data; growth re-rating |
| AST SpaceMobile | ASTS | n/a | n/a | n/a | n/a | 0% | negative | Q1'26 rev $14.7M vs $36.6M est — 60% miss |
| Iridium | IRDM | n/a | n/a | n/a | n/a (pays a dividend) | positive (profitable) | the profitable incumbent comp | |
| SpaceX | private | n/a — private (IPO chatter 2026) | n/a | n/a | n/a | n/a | the elephant; possible 2026 IPO | |
Read: RKLB at ~64x EV/sales is priced like a software hypergrowth name, not a hardware/aerospace manufacturer (the aerospace-&-defense median is a tiny fraction of that). GuruFocus pegs "GF Value" at $15.75 vs. a ~$104 price — i.e., the model says deeply overvalued; treat that as a sentiment data point, not gospel, but the direction is unambiguous. The bull's own math only works on out-year revenue: $1.1–1.2B FY27 revenue × 60–65x EV/sales → ~$120–140. That is a multiple-on-multiple bet: you must believe both that FY27 revenue triples-from-here and that the market keeps paying ~60x sales after Neutron is flying and de-risked (when multiples usually compress). The comps verdict: the company is best-in-class; the multiple is the position's entire risk.
Caveat: I could not source clean EV/Sales multiples for PL, ASTS, IRDM — marked n/a rather than fabricated. A refresh with a market-data pull should populate this table.
Lens 8 · Stock-Price Catalysts (what actually moves RKLB)
Pattern over the last ~18 months — the stock reacts to (a) Neutron milestones/slips and (b) large government contracts, far more than to quarterly EPS:
- +22.1% on the $816M SDA Tracking Layer Tranche 3 award (Dec 2025) — single biggest single-day catalyst; the market re-rated the national-security revenue line.
- Neutron delay (Nov 2025, 2025→2026 slip) — pressured the stock; Neutron timing is the dominant swing factor.
- Sector beta is huge: RKLB moves with the whole space complex. Examples: +6% on a "SpaceX IPO lifts the sector" day (May 2026); −13% on a "space divergence" risk-off day (Jun 1 2026); a drop on Nasdaq-100 inclusion mechanics.
- Momentum/retail flow: +366% YoY with a $25→$151 range tells you positioning and narrative (Neutron + Golden Dome + SpaceX-comp halo) dominate over fundamentals quarter-to-quarter.
What the market reacts to: Neutron progress, defense primes, and sector sentiment — not the income statement. That means the catalyst calendar (next: Neutron first flight, late 2026) matters more than the next print.
Phase C — Judge people & books
Lens 9 · Management
- Track record (strong). Peter Beck (Founder/CEO/Chairman) built Rocket Lab from a New Zealand garage into the #2 Western launch provider — Electron is a genuine, repeatable engineering achievement (50+ launches, in-house Rutherford engine, 3D-printing, then the Photon bus and a serial acquisition machine). He has delivered hardware, repeatedly, which is rare in this sector.
- Tenure & skin in the game (high, but trimming). Beck holds ~51M shares (the largest insider position) — meaningful alignment. But he has been a net seller: ~5.0M shares net over ~18 months, including ~1.44M shares for ~$70M in Sept 2025; insiders collectively sold ~$196M over two years. That's a governance yellow flag (see Lens 10) — though for a founder of 18 years at an all-time-high stock, some diversification is normal.
- Capital allocation (aggressive, vertically-integrating, dilutive). The strategy is buy the supply chain: Sinclair, PSC, ASI, SolAero, Geost ($275M), Mynaric ($155M) — funded substantially in stock, plus equity raises (cash jumped $829M→$1.48B in Q1'26). Shares out are ~528.7M, up ~25% in the past year. The bet: spend now to own the full stack before the constellation buildout. ROE/ROIC are negative (pre-profit), so the capital-allocation verdict is unprovable until Neutron + Space Systems generate returns.
- Red flags: founder net-selling into the rally; heavy stock-funded M&A + raises = persistent dilution; Beck holds the combined CEO + Chairman role (concentration of control). None are smoking guns; all are worth monitoring.
- Archetype: quintessential founder-engineer-operator — visionary, hardware-credible, vertically-integrating empire-builder. For this stage (scaling from launch to space prime), that's the right archetype — provided the balance-sheet discipline holds.
Lens 10 · Forensic Red Flags
Acting as a forensic equity analyst. Figures `` from company 8-Ks; SEC enforcement from the Step-0 regulatory file.
Accounting / quality-of-earnings risks:
- Non-GAAP vs. GAAP gap is structural and SBC-driven. Q1'26 non-GAAP GM 43.0% vs GAAP 38.2%; the company guides and is celebrated on non-GAAP. Stock-based comp + acquisition amortization (Geost/Mynaric) flatter the adjusted numbers. Watch the SBC line — with ~25% annual share growth, dilution is a real cost the adjusted metrics suppress.
- Goodwill & intangibles build-up. Six acquisitions (SolAero/Geost/Mynaric the largest) load the balance sheet with goodwill/intangibles. An impairment risk exists if any acquired unit (e.g., a merchant Mynaric terminal business) underperforms — a non-cash hit that would dent GAAP book value.
- Backlog ≠ revenue, and is long-dated. The $2.2B backlog is the headline bull metric, but ~$1.3B is the SDA program delivering through ~2029 — i.e., heavily concentrated and multi-year. Backlog quality (cancellation/renegotiation terms on government work) is the thing to interrogate.
- Cash burn vs. earnings divergence. FY2025 operating cash flow $(165.5)M against a GAAP net loss of $(198.2)M; the company funds itself with equity raises, not operations. This is normal for a pre-profit hardware scaler, but it is the defining balance-sheet fact: the equity story is funded by selling equity.
- Neutron capex/cost creep. Neutron development ran from a "$250–300M" estimate to ~$360M spent through end-2025 — a ~20%+ overrun. Cost discipline on the critical program is a forensic watch-item.
Regulatory findings (required sub-section):
- SEC Litigation Releases / AAERs: None. Per
regulatory/regulatory-findings.md (generated 2026-06-17 via SEC EDGAR EFTS, LR + AAER, period 2021-06-17→2026-06-17): 0 SEC findings. (Note: the LR EFTS query hit a transient HTTP 500 during the run; AAER returned clean. No LR hits are expected for this name, but a future refresh should re-confirm the LR side.)
- Non-SEC enforcement (web search): No material FTC/DOJ/FDA/CFPB enforcement actions, consent decrees, fines, or penalties surfaced against Rocket Lab in web search as of 2026-06-17.
- 10-K Item 3 (Legal Proceedings): Not retrieved in this web-only run (no
filings/ in the research layer; WAVE constraint prohibits ingest-filing.ts). Open item for refresh: pull FY2025 10-K Item 3 to confirm no material litigation. Routine commercial-space disputes/ITAR-compliance exposure are the category to check.
- Verdict: No material regulatory or legal findings via SEC EDGAR EFTS (LR + AAER) and web search as of 2026-06-17; 10-K Item 3 confirmation deferred to the next (research-layer-grounded) refresh.
Phase D — Project & stress-test
Lens 11 · Forward Projection (FY2026E / FY2027E / FY2028E)
Bottom-up from the latest actuals + guidance. Every input labeled; outputs ``. No forecast.ts create logged — unattended breadth loop per the watchlist rules.
Anchors:
- FY2025 actual revenue $601.8M (+38%).
- Q1'26 $200.3M; Q2'26 guide $225–240M (midpoint ~$232M). Annualizing the H1 run-rate and the order book → company/Street FY2026 ~$880M (+~47%); some analyst models use ~$850M.
- Street FY2027 ~$1.1–1.2B; first GAAP profit (~$0.08 EPS) modeled in 2027.
| Scenario | FY2026E rev | FY2027E rev | FY2028E rev | FY2026 adj-EBITDA | EPS path |
|---|
| Bear | ~$840M | ~$1.0B | ~$1.2B (Neutron slips/limited cadence) | loss ~$(60)M | GAAP loss through 2027 |
| Base | ~$880M (+47%) | ~$1.15B (+31%) | ~$1.6B (Neutron ramps + SDA deliveries) | loss ~$(40)M, narrowing | first GAAP profit 2027 ($0.05–0.10) |
| Bull | ~$920M | ~$1.3B | ~$2.0B+ (Neutron at cadence + own-constellation + Golden Dome) | near breakeven 2026 | GAAP profit 2027, scaling 2028 |
Logic: Space Systems (~60–68% of mix, SDA-anchored, ~$1.3B contracted) gives a visible base growing ~40–50%. Launch is optionality: the entire bull-vs-bear gap in FY2028 is Neutron cadence — does it reach a reliable, multi-launch-per-year rhythm at a $55M price with 40–50% target margins, or does it stay a single-digit-launches science project through 2028? Operating leverage is real (margins beat in Q1'26), but the Q2 guide-down warns it's non-linear. Dilution (~25%/yr historically; likely moderating as cash sits at $1.48B) is a persistent EPS headwind.
The base call (for a future tracked forecast): RKLB FY2027 (Dec-2027) GAAP profitable / non-GAAP EPS ≥ $0.10, p≈0.45 — genuinely uncertain; hinges on Neutron flying and ramping on schedule. (Not logged via forecast.ts — breadth-loop rule.)
Lens 12 · Bull vs Bear
Bull case. Rocket Lab is the only vertically-integrated, full-stack, Western alternative to SpaceX — and the market is desperate for a SpaceX alternative (national security, commercial diversification, anti-single-point-of-failure). It compounds revenue ~40–50% with a $2.2B backlog (+108% YoY), is approaching EBITDA breakeven, has $1.48B cash, and owns a national-security moat (SDA prime, Geost payloads, Golden Dome exposure) that is nearly impossible to replicate. Neutron is a free call option the market hasn't fully de-risked: if it flies and ramps, Rocket Lab unlocks the medium-lift + megaconstellation TAM and re-rates as a space prime, not a small-launch niche player. Flatellite + Neutron + owned payloads could make Rocket Lab a constellation operator (recurring space-services revenue), not just a contractor — the highest-value endgame. Earnings-surprise potential: every quarter of margin beats + a successful Neutron debut.
Bear case (2–3 permanent-impairment risks).
- Neutron fails or chronically slips. It has already slipped once (2025→2026) and run
20% over budget ($360M). If the maiden flight fails or the program stretches to 2028+, the entire re-rating thesis evaporates and the stock is left at ~64x sales on a small-launch + components business.
- SpaceX crushes the launch economics. Neutron's 13,000 kg < Falcon 9's 17,500 kg < Starship's ~150 t. SpaceX can price Falcon 9 rideshare at ~$67–70M and cut prices to undercut Neutron's $55M target at will — capping Rocket Lab's projected 40–50% launch margins. Rocket Lab is a price-taker in its franchise market.
- The multiple compresses. At ~64x EV/sales (295% above its own 10-yr median; GF Value $15.75), even flawless execution can produce a flat-to-down stock as the multiple normalizes. The valuation is the risk.
Pre-mortem (18 months out, thesis broke): Most likely path — Neutron's maiden flight slips into 2027 (or fails), SpaceX announces aggressive medium-lift/Starship pricing, a risk-off rotation hits unprofitable space/momentum names, and RKLB de-rates from ~64x to ~20–25x sales: a 50–60% drawdown even with revenue growing. Secondary path — a Geost/Mynaric integration stumble + goodwill impairment dents GAAP book and confidence.
Are multiples too high? Yes, on any conventional metric. The only frame in which ~64x sales is defensible is "pre-revenue-scale platform with a near-term inflection (Neutron) + a software-like constellation-services endgame." That's a narrative multiple, not a numbers multiple.
Contrarian view (what the market refuses to see): The bull crowd treats Neutron as ~certain and treats vertical integration as pure moat. The contrarian read is that vertical integration at this pace is also a capex/dilution/integration-risk machine, and that Rocket Lab's durable moat is national security, not launch cost — which means the right comp is a high-growth defense-tech prime (clearances, programs, ITAR) trading at maybe 8–15x sales, not a 60x software comp. If the market ever recodes RKLB from "space-growth" to "defense-prime," the multiple halves regardless of execution.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case.
- What structurally breaks the money machine: Rocket Lab doesn't actually have pricing power in launch — its anchor franchise. It survives on (a) being a SpaceX alternative and (b) government programs. SpaceX is one pricing decision away from compressing Neutron's economics; the DoD is one budget/политика shift away from re-allocating the SDA/Golden Dome spend. Neither lever is in Rocket Lab's hands.
- Revenue concentration: ~$1.3B of the $2.2B backlog is the SDA program — a single government customer/program. If SDA Tranche timelines stretch, get re-scoped, or the next tranche goes to a competitor (L3Harris, Lockheed, York, Terran Orbital-type players), the backlog's quality collapses. Concentration in a single multi-year defense program is the hidden fragility under the "diversified" story.
- Moat weaker than bulls think: "vertical integration" is also a euphemism for "we had to buy six companies and dilute 25%/yr because none of these capabilities existed in-house." Each acquisition is integration + culture + impairment risk. The composites/engine IP is real, but it's not a network effect or a switching-cost moat — it's an engineering lead that SpaceX, Blue Origin, Firefly, Stoke, and Relativity are all racing to erase.
- Most dangerous competitor bulls underestimate: not SpaceX (everyone sees that) — it's the reusable-medium-lift cohort behind Neutron (Blue Origin New Glenn, Stoke Space, a re-financed Relativity, Firefly+Northrop) plus a potential SpaceX IPO that gives public investors direct access to the category leader and drains RKLB's "only-way-to-own-space" premium.
- Worst capital-allocation moves: stock-funded M&A at a sky-high multiple + founder net-selling ~$70M into the rally + 25% dilution. Bulls call it "building the stack"; a short calls it "printing shares while the narrative is hot."
- Assumptions that must hold for today's ~$104 price: (1) Neutron flies and ramps on schedule at target economics; (2) the market keeps paying ~60x sales after de-risking; (3) SpaceX doesn't price-war; (4) SDA funding holds and renews; (5) no goodwill impairment; (6) dilution moderates. All six.
- If growth disappoints 20–30%: FY2027 revenue ~$0.8–0.9B instead of $1.1–1.2B → the bull's own valuation math ($1.1–1.2B × 60–65x) breaks → fair value drops toward ~$70–90 on the bull framework, and toward GuruFocus's ~$16 on a normalized one. Asymmetry is to the downside at this price.
- Single scenario that permanently impairs the business: a catastrophic Neutron maiden-flight failure (loss of vehicle + multi-year requalification) coincident with a SpaceX medium-lift price cut — would strand the medium-lift thesis, force more dilutive raises into a falling stock, and recode RKLB as a sub-scale launch+components shop. Plausibility: moderate (maiden flights fail often; SpaceX pricing is real) — not tail-risk-remote.
Lens 14 · Management Questions (15, ordered by information value)
- Neutron: What is the specific gating item between today and the maiden flight, and what is the realistic probability the first orbital flight occurs in calendar 2026 vs. slipping to 2027?
- On Neutron unit economics: at what launch cadence does Neutron hit the 40–50% gross-margin target, and what is the breakeven cadence if SpaceX cuts Falcon 9 / Starship pricing 20%?
- Customer concentration: what % of the $2.2B backlog is the SDA/Golden Dome program, and what are the cancellation/re-scope terms if DoD tranche timelines shift?
- What is the planned share-count trajectory — do you expect dilution to continue at the recent ~25%/yr pace, and under what conditions would you stop issuing equity given the $1.48B cash balance?
- Walk through the path to GAAP profitability (not just adjusted EBITDA): which year, and what are the 2–3 biggest swing factors?
- On the acquisition strategy (Geost, Mynaric): what are the integration milestones and the impairment-test assumptions, and how do you avoid goodwill write-downs if a merchant unit underperforms?
- Why should RKLB trade as a high-growth platform (~60x sales) rather than as a defense-tech prime (~10–15x sales)? What recurring, software-like revenue actually justifies the multiple?
- Flatellite / own-constellation: are you committing capital to operate your own constellation (becoming a recurring space-services operator), and how do you fund that without competing for capital against Neutron?
- How do you think about the SpaceX IPO as a competitive and capital-markets event — does direct public access to SpaceX change your cost of capital or customer pipeline?
- What is the realistic medium-lift TAM you can win given New Glenn, Stoke, Firefly/Northrop, and Relativity all targeting the same reusable-medium-lift niche?
- On the Q2'26 gross-margin step-down: is the Space-Systems mix structurally lower-margin, and where does blended gross margin settle at scale?
- HASTE/hypersonics: how durable and how large is the defense hypersonic-test revenue line, and is it tied to specific multi-year programs?
- How exposed is the business to ITAR/export-control and the foreign (NZ/Germany via Mynaric) operations under a more protectionist US defense-procurement posture?
- What is your make-vs-buy framework going forward — is the acquisition phase substantially complete, or should we expect more stock-funded deals?
- Capital allocation: at what point do buybacks or self-funded growth replace equity issuance, and what ROIC hurdle do you hold acquisitions to?